CONMED Corp (NYSE: CNMD) grants CFO stock options and RSUs
Rhea-AI Filing Summary
Gallagher John E reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp Executive Vice President & CFO John E. Gallagher received equity awards on July 15, 2026, including 30,536 stock options to purchase common shares at $42.79 per share and RSU grants of 26,875 and 35,054 shares under the Company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years (33%, 33%, 34% annually), while the stock options generally vest over four years in equal 25% installments, beginning one year after the grant date, and expire on July 15, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Gallagher John E
Role
Executive Vice President & CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | RSUs (Restricted Stock Units) | 35,054 | $0.00 | -- |
| Grant/Award | RSUs (Restricted Stock Units) | 26,875 | $0.00 | -- |
| Grant/Award | Options To Purchase Common Stock | 30,536 | $0.00 | -- |
Holdings After Transaction:
RSUs (Restricted Stock Units) — 35,054 shares (Direct);
Options To Purchase Common Stock — 30,536 shares (Direct)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year. The stock options were granted under CONMED Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.
Key Figures
Stock options granted: 30,536 options
Option exercise price: $42.79 per share
RSUs granted (tranche 1): 26,875 RSUs
+2 more
5 metrics
Stock options granted
30,536 options
Grant to Executive Vice President & CFO on July 15, 2026
Option exercise price
$42.79 per share
Exercise price for 30,536 options granted July 15, 2026
RSUs granted (tranche 1)
26,875 RSUs
Restricted stock units referencing common stock, granted July 15, 2026
RSUs granted (tranche 2)
35,054 RSUs
Additional restricted stock units referencing common stock, granted July 15, 2026
Option expiration date
July 15, 2036
Expiration for stock options granted to the CFO under 2025 Long-Term Incentive Plan
Key Terms
Restricted Stock Units, Long-Term Incentive Plan, stock options, vesting
4 terms
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Long-Term Incentive Plan financial
"subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan"
A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.
stock options financial
"The stock options were granted under CONMED Corporation's 2025 Long-Term Incentive Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vesting financial
"generally vesting over a three-year period with the first 33% of the RSUs vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did CNMD’s CFO John Gallagher receive on July 15, 2026?
On July 15, 2026, John E. Gallagher received 30,536 stock options with a $42.79 exercise price and two RSU grants covering 26,875 and 35,054 shares of CONMED common stock, all under the Company’s 2025 Long-Term Incentive Plan.
What are the terms of the new CONMED (CNMD) stock options granted to the CFO?
The grant consists of 30,536 stock options to purchase CONMED common stock at an exercise price of $42.79 per share. These options generally vest over four years in equal 25% installments, beginning one year after the July 15, 2026 grant date, and expire July 15, 2036.
How do the new RSUs for CNMD’s CFO vest over time?
The RSU awards of 26,875 and 35,054 shares each represent rights to receive one CONMED common share per unit. They generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years.
Under which plan were the CNMD equity awards to the CFO granted?
Both the stock options and RSUs granted to John E. Gallagher were issued under CONMED’s 2025 Long-Term Incentive Plan. This plan governs the terms, including vesting schedules, for the executive’s equity-based compensation awards reported in this insider transaction disclosure.
Does this CNMD insider report show any stock sales by the CFO?
No. The reported transactions are all acquisitions of derivative securities: grants of stock options and RSUs. There are no sales or other dispositions of CONMED common stock or derivatives by John E. Gallagher disclosed in this report.